Concise Reviews:Embryonic Stem Cells/Induced Pluripotent Stem Cells

You have free access to this content

Concise Review: Induced Pluripotent Stem Cells and Lineage Reprogramming: Prospects for Bone Regeneration†‡§

  1. Damir J. Illich1,¶,*,
  2. Necati Demir1,
  3. Miodrag Stojković2,3,
  4. Martin Scheer4,
  5. Daniel Rothamel4,
  6. Jörg Neugebauer4,
  7. Jürgen Hescheler1,5,
  8. Joachim E. Zöller4

Article first published online: 5 APR 2011

DOI: 10.1002/stem.611

Issue

STEM CELLS

STEM CELLS

Volume 29, Issue 4, pages 555–563, April 2011

Additional Information

How to Cite

Illich, D. J., Demir, N., Stojković, M., Scheer, M., Rothamel, D., Neugebauer, J., Hescheler, J. and Zöller, J. E. (2011), Concise Review: Induced Pluripotent Stem Cells and Lineage Reprogramming: Prospects for Bone Regeneration. STEM CELLS, 29: 555–563. doi: 10.1002/stem.611

Author Information

  1. 1

    Medical Center, Institute for Neurophysiology, University of Cologne, Cologne, Germany

  2. 2

    Spebo Medical, Leskovac, Serbia

  3. 3

    Human Genetics, Medical Faculty, University of Kragujevac, Kragujevac, Serbia

  4. 4

    Department for Oral and Cranio-maxillo and Facial Plastic Surgery, University of Cologne, Cologne, Germany

  5. 5

    Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany

  1. Ph: +49 176 23506833; Fax: +49 221 478 6965

*Medical Center, Institute for Neurophysiology, University of Cologne, Robert-Koch-Straße 39, Cologne 50931, Germany

  1. †

    Disclosure of potential conflicts of interest is found at the end of this article.

  2. ‡

    Author contributions: D.J.I.: conception and design, collection and/or assembly of data, data analysis and interpretation, manuscript writing; N.D.: collection and/or assembly of data, data analysis and interpretation, manuscript writing; M. Stojković: data analysis and interpretation, final approval of manuscript; M.S., D.R., and J.H.: data analysis and interpretation; J.N.: administrative support; J.E.Z.: final approval of manuscript.

  3. §

    First published online in STEM CELLSEXPRESS February 4, 2011.

  4. Ph: +49 176 23506833; Fax: +49 221 478 6965

Publication History

  1. Issue published online: 5 APR 2011
  2. Article first published online: 5 APR 2011
  3. Accepted manuscript online: 4 FEB 2011 10:39AM EST
  4. Manuscript Accepted: 18 JAN 2011
  5. Manuscript Received: 26 AUG 2010

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (235K)

References

  • 1
    Rawashdeh MA, Telfah H. Secondary alveolar bone grafting: The dilemma of donor site selection and morbidity. Br J Oral Maxillofac Surg 2008; 46: 665–670.
  • 2
    Warnke PH, Springer IN, Wiltfang J et al. Growth and transplantation of a custom vascularised bone graft in a man. Lancet 2004; 364: 766–770.
  • 3
    Quarto R, Mastrogiacomo M, Cancedda R et al. Repair of large bone defects with the use of autologous bone marrow stromal cells. N Engl J Med 2001; 344: 385–386.
  • 4
    Horwitz EM, Prockop DJ, Fitzpatrick LA et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 1999; 5: 309–313.
  • 5
    Whyte MP, Kurtzberg J, McAlister WH et al. Marrow cell transplantation for infantile hypophosphatasia. J Bone Miner Res 2003; 18: 624–636.
  • 6
    Sethe S, Scutt A, Stolzing A. Aging of mesenchymal stem cells. Ageing Res Rev 2006; 5: 91–116.
  • 7
    Martin GR. Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Proc Natl Acad Sci USA 1981; 78: 7634–7638.
  • 8
    Thomson JA, Itskovitz-Eldor J, Shapiro SS et al. Embryonic stem cell lines derived from human blastocysts. Science 1998; 282: 1145–1147.
  • 9
    Gurdon JB, Melton DA. Nuclear reprogramming in cells. Science 2008; 322: 1811–1815.
  • 10
    Takahashi K, Tanabe K, Ohnuki M et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131: 861–872.
  • 11
    Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663–676.
  • 12
    Yu J, Vodyanik MA, Smuga-Otto K et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318: 1917–1920.
  • 13
    Cai J, Yang M, Poremsky E et al. Dopaminergic neurons derived from human induced pluripotent stem cells survive and integrate into 6-OHDA lesioned rats. Stem Cells Dev 2010; 19: 1017–1023.
  • 14
    Tateishi K, He J, Taranova O et al. Generation of insulin-secreting islet-like clusters from human skin fibroblasts. J Biol Chem 2008; 283: 31601–31607.
  • 15
    Zhang J, Wilson GF, Soerens AG et al. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res 2009; 104: e30–e41.
  • 16
    Stojkovic M, Stojkovic P, Leary C et al. Derivation of a human blastocyst after heterologous nuclear transfer to donated oocytes. Reprod Biomed Online 2005; 11: 226–231.
  • 17
    Hanna J, Saha K, Pando B et al. Direct cell reprogramming is a stochastic process amenable to acceleration. Nature 2009; 462: 595–601.
  • 18
    Yamanaka S. Elite and stochastic models for induced pluripotent stem cell generation. Nature 2009; 460: 49–52.
  • 19
    Shi Y, Do JT, Desponts C et al. A combined chemical and genetic approach for the generation of induced pluripotent stem cells. Cell Stem Cell 2008; 2: 525–528.
  • 20
    Huangfu D, Maehr R, Guo W et al. Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat Biotechnol 2008; 26: 795–797.
  • 21
    Li W, Wei W, Zhu S et al. Generation of rat and human induced pluripotent stem cells by combining genetic reprogramming and chemical inhibitors. Cell Stem Cell 2009; 4: 16–19.
  • 22
    Lin T, Ambasudhan R, Yuan X et al. A chemical platform for improved induction of human iPSCs. Nat Methods 2009; 6: 805–808.
  • 23
    Li W, Zhou H, Abujarour R et al. Generation of human induced pluripotent stem cells in the absence of exogenous Sox2. Stem Cells 2009; 27: 2992–3000.
  • 24
    Marson A, Foreman R, Chevalier B et al. Wnt signaling promotes reprogramming of somatic cells to pluripotency. Cell Stem Cell 2008; 3: 132–135.
  • 25
    Ichida JK, Blanchard J, Lam K et al. A small-molecule inhibitor of tgf-Beta signaling replaces sox2 in reprogramming by inducing nanog. Cell Stem Cell 2009; 5: 491–503.
  • 26
    Stadtfeld M, Nagaya M, Utikal J et al. Induced pluripotent stem cells generated without viral integration. Science 2008; 322: 945–949.
  • 27
    Gonzalez F, Barragan Monasterio M, Tiscornia G et al. Generation of mouse-induced pluripotent stem cells by transient expression of a single nonviral polycistronic vector. Proc Natl Acad Sci USA 2009; 106: 8918–8922.
  • 28
    Kaji K, Norrby K, Paca A et al. Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature 2009; 458: 771–775.
  • 29
    Woltjen K, Michael IP, Mohseni P et al. piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 2009; 458: 766–770.
  • 30
    Yu J, Hu K, Smuga-Otto K et al. Human induced pluripotent stem cells free of vector and transgene sequences. Science 2009; 324: 797–801.
  • 31
    Kim D, Kim CH, Moon JI et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell 2009; 4: 472–476.
  • 32
    Zhou H, Wu S, Joo JY et al. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell 2009; 4: 381–384.
  • 33
    Rowntree RK, McNeish JD. Induced pluripotent stem cells: Opportunities as research and development tools in 21st century drug discovery. Regen Med 2010; 5: 557–568.
  • 34
    Rubin LL. Stem cells and drug discovery: The beginning of a new era? Cell 2008; 132: 549–552.
  • 35
    Park IH, Arora N, Huo H et al. Disease-specific induced pluripotent stem cells. Cell 2008; 134: 877–886.
  • 36
    Dimos JT, Rodolfa KT, Niakan KK et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 2008; 321: 1218–1221.
  • 37
    Lee G, Papapetrou EP, Kim H et al. Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature 2009; 461: 402–406.
  • 38
    Hanna J, Wernig M, Markoulaki S et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 2007; 318: 1920–1923.
  • 39
    Raya A, Rodriguez-Piza I, Guenechea G et al. Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature 2009; 460: 53–59.
  • 40
    Wernig M, Zhao JP, Pruszak J et al. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proc Natl Acad Sci USA 2008; 105: 5856–5861.
  • 41
    Xu D, Alipio Z, Fink LM et al. Phenotypic correction of murine hemophilia A using an iPS cell-based therapy. Proc Natl Acad Sci USA 2009; 106: 808–813.
  • 42
    Davis RL, Weintraub H, Lassar AB. Expression of a single transfected cDNA converts fibroblasts to myoblasts. Cell 1987; 51: 987–1000.
  • 43
    Choi J, Costa ML, Mermelstein CS et al. MyoD converts primary dermal fibroblasts, chondroblasts, smooth muscle, and retinal pigmented epithelial cells into striated mononucleated myoblasts and multinucleated myotubes. Proc Natl Acad Sci USA 1990; 87: 7988–7992.
  • 44
    Schafer BW, Blakely BT, Darlington GJ et al. Effect of cell history on response to helix-loop-helix family of myogenic regulators. Nature 1990; 344: 454–458.
  • 45
    Cobaleda C, Jochum W, Busslinger M. Conversion of mature B cells into T cells by dedifferentiation to uncommitted progenitors. Nature 2007; 449: 473–477.
  • 46
    Xie H, Ye M, Feng R et al. Stepwise reprogramming of B cells into macrophages. Cell 2004; 117: 663–676.
  • 47
    Feng R, Desbordes SC, Xie H et al. PU. 1 and C/EBPalpha/beta convert fibroblasts into macrophage-like cells. Proc Natl Acad Sci USA 2008; 105: 6057–6062.
  • 48
    Kondo T, Raff M. Oligodendrocyte precursor cells reprogrammed to become multipotential CNS stem cells. Science 2000; 289: 1754–1757.
  • 49
    Vierbuchen T, Ostermeier A, Pang ZP et al. Direct conversion of fibroblasts to functional neurons by defined factors. Nature 2010; 463: 1035–1041.
  • 50
    Takeuchi JK, Bruneau BG. Directed transdifferentiation of mouse mesoderm to heart tissue by defined factors. Nature 2009; 459: 708–711.
  • 51
    Ieda M, Fu JD, Delgado-Olguin P et al. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell 2010; 142: 375–386.
  • 52
    Izumikawa M, Minoda R, Kawamoto K et al. Auditory hair cell replacement and hearing improvement by Atoh1 gene therapy in deaf mammals. Nat Med 2005; 11: 271–276.
  • 53
    Kawamoto K, Ishimoto S, Minoda R et al. Math1 gene transfer generates new cochlear hair cells in mature guinea pigs in vivo. J Neurosci 2003; 23: 4395–4400.
  • 54
    Zheng JL, Gao WQ. Overexpression of Math1 induces robust production of extra hair cells in postnatal rat inner ears. Nat Neurosci 2000; 3: 580–586.
  • 55
    Zhou Q, Brown J, Kanarek A et al. In vivo reprogramming of adult pancreatic exocrine cells to beta-cells. Nature 2008; 455: 627–632.
  • 56
    Horwitz EM, Gordon PL, Koo WK et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci USA 2002; 99: 8932–8937.
  • 57
    Undale AH, Westendorf JJ, Yaszemski MJ et al. Mesenchymal stem cells for bone repair and metabolic bone diseases. Mayo Clin Proc 2009; 84: 893–902.
  • 58
    Lendeckel S, Jodicke A, Christophis P et al. Autologous stem cells (adipose) and fibrin glue used to treat widespread traumatic calvarial defects: Case report. J Craniomaxillofac Surg 2004; 32: 370–373.
  • 59
    Marcacci M, Kon E, Moukhachev V et al. Stem cells associated with macroporous bioceramics for long bone repair: 6- to 7-year outcome of a pilot clinical study. Tissue Eng 2007; 13: 947–955.
  • 60
    Sottile V, Thomson A, McWhir J. In vitro osteogenic differentiation of human ES cells. Cloning Stem Cells 2003; 5: 149–155.
  • 61
    Kawaguchi J, Mee PJ, Smith AG. Osteogenic and chondrogenic differentiation of embryonic stem cells in response to specific growth factors. Bone 2005; 36: 758–769.
  • 62
    Phillips BW, Belmonte N, Vernochet C et al. Compactin enhances osteogenesis in murine embryonic stem cells. Biochem Biophys Res Commun 2001; 284: 478–484.
  • 63
    zur Nieden NI, Kempka G, Ahr HJ. In vitro differentiation of embryonic stem cells into mineralized osteoblasts. Differentiation 2003; 71: 18–27.
  • 64
    Bielby RC, Boccaccini AR, Polak JM et al. In vitro differentiation and in vivo mineralization of osteogenic cells derived from human embryonic stem cells. Tissue Eng 2004; 10: 1518–1525.
  • 65
    zur Nieden NI, Price FD, Davis LA et al. Gene profiling on mixed embryonic stem cell populations reveals a biphasic role for beta-catenin in osteogenic differentiation. Mol Endocrinol 2007; 21: 674–685.
  • 66
    Ahn SE, Kim S, Park KH et al. Primary bone-derived cells induce osteogenic differentiation without exogenous factors in human embryonic stem cells. Biochem Biophys Res Commun 2006; 340: 403–408.
  • 67
    Heng BC, Toh WS, Pereira BP et al. An autologous cell lysate extract from human embryonic stem cell (hESC) derived osteoblasts can enhance osteogenesis of hESC. Tissue Cell 2008; 40: 219–228.
  • 68
    Duplomb L, Dagouassat M, Jourdon P et al. Differentiation of osteoblasts from mouse embryonic stem cells without generation of embryoid body. In Vitro Cell Dev Biol Anim 2007; 43: 21–24.
  • 69
    Zur Nieden NI, Davis LA, Rancourt DE. Monolayer cultivation of osteoprogenitors shortens duration of the embryonic stem cell test while reliably predicting developmental osteotoxicity. Toxicology 2010.
  • 70
    Karp JM, Ferreira LS, Khademhosseini A et al. Cultivation of human embryonic stem cells without the embryoid body step enhances osteogenesis in vitro. Stem Cells 2006; 24: 835–843.
  • 71
    Tashiro K, Inamura M, Kawabata K et al. Efficient adipocyte and osteoblast differentiation from mouse induced pluripotent stem cells by adenoviral transduction. Stem Cells 2009; 27: 1802–1811.
  • 72
    Kao CL, Tai LK, Chiou SH et al. Resveratrol promotes osteogenic differentiation and protects against dexamethasone damage in murine induced pluripotent stem cells. Stem Cells Dev 2010; 19: 247–258.
  • 73
    Li F, Bronson S, Niyibizi C. Derivation of murine induced pluripotent stem cells (iPS) and assessment of their differentiation toward osteogenic lineage. J Cell Biochem 2010; 109: 643–652.
  • 74
    Lian Q, Zhang Y, Zhang J et al. Functional mesenchymal stem cells derived from human induced pluripotent stem cells attenuate limb ischemia in mice. Circulation 2010; 121: 1113–1123.
  • 75
    Bilousova G, Hyun Jun D, King KB et al. Osteoblasts derived from induced pluripotent stem cells form calcified structures in scaffolds both in vitro and in vitro. Stem Cells. 10.1002/stem.566.
  • 76
    Kim S, Kim SS, Lee SH et al. In vivo bone formation from human embryonic stem cell-derived osteogenic cells in poly(D, L-lactic-co-glycolic acid)/hydroxyapatite composite scaffolds. Biomaterials 2008; 29: 1043–1053.
  • 77
    Tremoleda JL, Forsyth NR, Khan NS et al. Bone tissue formation from human embryonic stem cells in vivo. Cloning Stem Cells 2008; 10: 119–132.
  • 78
    Arpornmaeklong P, Brown SE, Wang Z et al. Phenotypic characterization, osteoblastic differentiation, and bone regeneration capacity of human embryonic stem cell-derived mesenchymal stem cells. Stem Cells Dev 2009; 18: 955–968.
  • 79
    Kuznetsov S, Cherman N, Gehron Robey P. In vivo bone formation by progeny of human embryonic stem cells. Stem Cells Dev 2010.
  • 80
    Duan X, Tu Q, Zhang J et al. Application of induced pluripotent stem (iPS) cells in periodontal tissue regeneration. J Cell Physiol 2011; 226: 150–157.
  • 81
    Aubin CE, Dansereau J, Petit Y et al. Three-dimensional measurement of wedged scoliotic vertebrae and intervertebral disks. Eur Spine J 1998; 7: 59–65.
  • 82
    Friedenstein AJ, Piatetzky S, II, Petrakova KV. Osteogenesis in transplants of bone marrow cells. J Embryol Exp Morphol 1966; 16: 381–390.
  • 83
    Lemischka IR, Raulet DH, Mulligan RC. Developmental potential and dynamic behavior of hematopoietic stem cells. Cell 1986; 45: 917–927.
  • 84
    Owen M, Friedenstein AJ. Stromal stem cells: Marrow-derived osteogenic precursors. Ciba Found Symp 1988; 136: 42–60.
  • 85
    Maria OM, Khosravi R, Mezey E et al. Cells from bone marrow that evolve into oral tissues and their clinical applications. Oral Dis 2007; 13: 11–16.
  • 86
    Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143–147.
  • 87
    Duplomb L, Dagouassat M, Jourdon P et al. Concise review: Embryonic stem cells: A new tool to study osteoblast and osteoclast differentiation. Stem Cells 2007; 25: 544–552.
  • 88
    Blelloch R, Wang Z, Meissner A et al. Reprogramming efficiency following somatic cell nuclear transfer is influenced by the differentiation and methylation state of the donor nucleus. Stem Cells 2006; 24: 2007–2013.
  • 89
    Hanna J, Markoulaki S, Schorderet P et al. Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency. Cell 2008; 133: 250–264.
  • 90
    Fujii M, Takeda K, Imamura T et al. Roles of bone morphogenetic protein type I receptors and Smad proteins in osteoblast and chondroblast differentiation. Mol Biol Cell 1999; 10: 3801–3813.
  • 91
    Hayashi M, Maeda S, Aburatani H et al. Pitx2 prevents osteoblastic transdifferentiation of myoblasts by bone morphogenetic proteins. J Biol Chem 2008; 283: 565–571.
  • 92
    Lee KS, Kim HJ, Li QL et al. Runx2 is a common target of transforming growth factor beta1 and bone morphogenetic protein 2, and cooperation between Runx2 and Smad5 induces osteoblast-specific gene expression in the pluripotent mesenchymal precursor cell line C2C12. Mol Cell Biol 2000; 20: 8783–8792.
  • 93
    Ouyang X, Fujimoto M, Nakagawa R et al. SOCS-2 interferes with myotube formation and potentiates osteoblast differentiation through upregulation of JunB in C2C12 cells. J Cell Physiol 2006; 207: 428–436.
  • 94
    Diaz Sanchez-Bustamante C, Kelm JM, Egermann M et al. Ectopic expression of delta FBJ murine osteosarcoma viral oncogene homolog B mediates transdifferentiation of adipose-like spheroids into osteo-like microtissues. Tissue Eng Part A 2008; 14: 1377–1394.
  • 95
    Kassem M, Abdallah BM, Saeed H. Osteoblastic cells: Differentiation and trans-differentiation. Arch Biochem Biophys 2008; 473: 183–187.
  • 96
    Schilling T, Noth U, Klein-Hitpass L et al. Plasticity in adipogenesis and osteogenesis of human mesenchymal stem cells. Mol Cell Endocrinol 2007; 271: 1–17.
  • 97
    Karner E, Backesjo CM, Cedervall J et al. Dynamics of gene expression during bone matrix formation in osteogenic cultures derived from human embryonic stem cells in vitro. Biochim Biophys Acta 2009; 1790: 110–118.
  • 98
    Karner E, Unger C, Sloan AJ et al. Bone matrix formation in osteogenic cultures derived from human embryonic stem cells in vitro. Stem Cells Dev 2007; 16: 39–52.
  • 99
    Cheng SL, Shao JS, Charlton-Kachigian N et al. MSX2 promotes osteogenesis and suppresses adipogenic differentiation of multipotent mesenchymal progenitors. J Biol Chem 2003; 278: 45969–45977.
  • 100
    Komori T. Regulation of osteoblast differentiation by transcription factors. J Cell Biochem 2006; 99: 1233–1239.
  • 101
    Miyama K, Yamada G, Yamamoto TS et al. A BMP-inducible gene, dlx5, regulates osteoblast differentiation and mesoderm induction. Dev Biol 1999; 208: 123–133.
  • 102
    Nakashima K, Zhou X, Kunkel G et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 2002; 108: 17–29.
  • 103
    Rice R, Rice DP, Olsen BR et al. Progression of calvarial bone development requires Foxc1 regulation of Msx2 and Alx4. Dev Biol 2003; 262: 75–87.
  • 104
    Franceschi RT. The developmental control of osteoblast-specific gene expression: Role of specific transcription factors and the extracellular matrix environment. Crit Rev Oral Biol Med 1999; 10: 40–57.
  • 105
    Jensen ED, Gopalakrishnan R, Westendorf JJ. Regulation of gene expression in osteoblasts. Biofactors 2010; 36: 25–32.
  • 106
    Komori T. Regulation of bone development and maintenance by Runx2. Front Biosci 2008; 13: 898–903.
  • 107
    Komori T, Yagi H, Nomura S et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997; 89: 755–764.
  • 108
    Heng BC, Cao T, Stanton LW et al. Strategies for directing the differentiation of stem cells into the osteogenic lineage in vitro. J Bone Miner Res 2004; 19: 1379–1394.
  • 109
    Justesen J, Pedersen SB, Stenderup K et al. Subcutaneous adipocytes can differentiate into bone-forming cells in vitro and in vivo. Tissue Eng 2004; 10: 381–391.
  • 110
    Nuttall ME, Patton AJ, Olivera DL et al. Human trabecular bone cells are able to express both osteoblastic and adipocytic phenotype: Implications for osteopenic disorders. J Bone Miner Res 1998; 13: 371–382.
  • 111
    Burkhardt R, Kettner G, Bohm W et al. Changes in trabecular bone, hematopoiesis and bone marrow vessels in aplastic anemia, primary osteoporosis, and old age: A comparative histomorphometric study. Bone 1987; 8: 157–164.
  • 112
    Justesen J, Stenderup K, Ebbesen EN et al. Adipocyte tissue volume in bone marrow is increased with aging and in patients with osteoporosis. Biogerontology 2001; 2: 165–171.
  • 113
    Abdallah BM, Haack-Sorensen M, Fink T et al. Inhibition of osteoblast differentiation but not adipocyte differentiation of mesenchymal stem cells by sera obtained from aged females. Bone 2006; 39: 181–188.
  • 114
    Gronthos S, Chen S, Wang CY et al. Telomerase accelerates osteogenesis of bone marrow stromal stem cells by upregulation of CBFA1, osterix, and osteocalcin. J Bone Miner Res 2003; 18: 716–722.
  • 115
    Simonsen JL, Rosada C, Serakinci N et al. Telomerase expression extends the proliferative life-span and maintains the osteogenic potential of human bone marrow stromal cells. Nat Biotechnol 2002; 20: 592–596.
  • 116
    Kajkenova O, Lecka-Czernik B, Gubrij I et al. Increased adipogenesis and myelopoiesis in the bone marrow of SAMP6, a murine model of defective osteoblastogenesis and low turnover osteopenia. J Bone Miner Res 1997; 12: 1772–1779.
  • 117
    Pieper AA, Xie S, Capota E et al. Discovery of a proneurogenic, neuroprotective chemical. Cell 2010; 142: 39–51.
  • 118
    Singhal N, Graumann J, Wu G et al. Chromatin-remodeling components of the BAF complex facilitate reprogramming. Cell 2010; 141: 943–955.
  • 119
    Taiani JT, Krawetz RJ, Zur Nieden NI et al. Reduced differentiation efficiency of murine embryonic stem cells in stirred suspension bioreactors. Stem Cells Dev 2010; 19: 989–998.
  • 120
    Chen S, Zhang Q, Wu X et al. Dedifferentiation of lineage-committed cells by a small molecule. J Am Chem Soc 2004; 126: 410–411.
View Full Article with Supporting Information (HTML) Get PDF (235K)